Brolucizumab and immunogenicity
Eye (Lond)
.
2020 Oct;34(10):1726-1728.
doi: 10.1038/s41433-020-0853-9.
Epub 2020 Apr 6.
Authors
Ashish Sharma
1
,
Nilesh Kumar
2
,
Nikulaa Parachuri
2
,
Rohini Sharma
3
,
Francesco Bandello
4
,
Baruch D Kuppermann
5
,
Anat Loewenstein
6
Affiliations
1
Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India. drashish79@hotmail.com.
2
Lotus Eye Hospital and Institute, Avinashi Road, Coimbatore, TN, India.
3
Department of Healthcare, The TIPS Global Institute, Coimbatore, TN, India.
4
University Vita-Salute, Scientific Institute San Raffaele, Milano, Italy.
5
Gavin Herbert Eye Institute, University of California, Irvine, CA, USA.
6
Division of Ophthalmology, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
PMID:
32251366
PMCID:
PMC7608337
DOI:
10.1038/s41433-020-0853-9
No abstract available
MeSH terms
Antibodies, Monoclonal, Humanized*
Humans
Intravitreal Injections
Substances
Antibodies, Monoclonal, Humanized
brolucizumab